The question at hand
Your company just acquired the rights to a set of pending patent applications. It's a standard intellectual property transaction, right? Maybe not. The FTC's recent amicus brief in the case against Amgen raises a question that you and your team should be asking: when does acquiring patent applications cross the line from legitimate IP strategy into anticompetitive conduct?
Traditionally, patents and patent applications are seen as government-granted rights, largely insulated from antitrust scrutiny. However, the FTC argues that transactions involving patent applications deserve the same antitrust analysis as any acquisition that might extend market power. This isn't just theoretical. It affects how you structure transactions, advise on patent strategy, and assess risk in industries where patents define competitive boundaries.
The case for antitrust immunity
The argument for treating patent application acquisitions as immune from antitrust review rests on three pillars.
First, patents are government-granted monopolies by design. Congress created the patent system to encourage innovation by giving inventors exclusive rights to their discoveries. Subjecting every patent-related transaction to antitrust scrutiny could undermine the incentive structure that drives R&D investment. Pharmaceutical companies, in particular, rely on patent protection to recoup the substantial costs of bringing new drugs to market. Treating patent acquisitions as potentially anticompetitive creates uncertainty that could chill legitimate innovation.
Second, the Noerr-Pennington doctrine protects companies from antitrust liability when they petition the government. When you acquire a pending patent application and then prosecute it before the U.S. Patent and Trademark Office, you're engaging in protected petitioning activity. The patent office is specifically designed to evaluate whether claims should be granted. Letting antitrust courts second-guess those decisions creates parallel proceedings that duplicate the patent office's expert function.
Third, there's a practical problem with line-drawing. If acquiring patent applications is subject to antitrust review, what about licensing them? What about hiring the inventor who filed them? Every transaction involving intellectual property becomes a potential antitrust landmine. Companies need clear rules, and the clearest rule is that patent-related conduct is evaluated under patent law, not antitrust law.
The case for antitrust scrutiny
The counterargument starts with a simple observation: acquiring a pending patent application is a commercial transaction between private parties. It happens before the government grants anything. The fact that the asset being acquired might later become a government-granted patent doesn't immunize the acquisition itself.
The FTC's brief in the Amgen case identifies why pending applications create unique anticompetitive risks. Unlike issued patents, applications can still be shaped. If you acquire applications and then use your control to craft claims that specifically cover a competitor's product or extend your existing monopoly, you're not just exercising a granted right. You're actively constructing barriers to entry.
Consider the pharmaceutical context. A company with a blockbuster biologic drug might acquire pending applications filed by others, then work with patent examiners to ensure the resulting patents cover not just the original invention, but also the company's own existing product. This isn't hypothetical. CareFirst alleges that Amgen acquired exclusive rights to patent applications with the potential to cover Enbrel, then shaped those applications to obtain claims that extended its monopoly and blocked biosimilar competitors.
The Noerr-Pennington doctrine protects petitioning the government, but it doesn't protect the underlying commercial deal. The FTC argues that prosecuting a patent application before the USPTO is protected activity. Enforcing an issued patent in court is protected activity. But the private agreement to acquire those applications isn't petitioning. It's a transaction that can be evaluated under the Clayton Act or Section 2 of the Sherman Act, just like any other acquisition that might substantially lessen competition.
There's also a policy argument. We want companies to innovate, but we don't want them to use IP transactions to maintain monopolies that keep drug prices high. The patent system is supposed to balance innovation incentives with eventual competition. If companies can use strategic patent application acquisitions to perpetually extend exclusivity, that balance breaks.
Where practitioners actually land
In practice, most legal and compliance teams treat patent acquisitions as IP transactions, not antitrust events. You run them through your standard IP due diligence process. You might flag them for Hart-Scott-Rodino Act review if they meet the size thresholds, but you're not typically conducting the kind of market analysis you'd do for a traditional merger.
That approach works fine when you're acquiring patents to practice the technology or to build a defensive portfolio. It gets riskier when the acquisition looks like a strategic move to block competitors. If your company already dominates a market and you're acquiring patent applications that could be shaped to cover competing products, you're in different territory.
The most sophisticated practitioners are starting to ask competitive effects questions earlier. When evaluating a patent application acquisition, they consider: Does our company already have significant market power? Could these applications be used to extend existing exclusivity? Are we acquiring them from a potential competitor? Could the claims be shaped in ways that block entry?
Our take
Patent application acquisitions should be subject to antitrust review, but not all of them warrant deep scrutiny. The distinction matters.
If you're a startup acquiring applications to build your core technology, antitrust risk is minimal. If you're a dominant firm acquiring applications that could extend your monopoly in a market where you already face limited competition, the calculus changes. The FTC's position isn't that every patent transaction violates antitrust law. It's that these transactions aren't automatically immune just because they involve IP.
For compliance and legal teams, this means updating your transaction review protocols. When evaluating patent application acquisitions, especially in concentrated markets, add these questions to your process: What market share does our company hold in the relevant space? Could these applications be prosecuted to cover products we already sell? Are we acquiring them from someone who might otherwise compete with us? What's our stated business justification?
Document your rationale. If the acquisition makes sense as part of a legitimate R&D strategy, say so clearly in your deal documents and board materials. If it's defensive, explain why. The Noerr-Pennington doctrine still protects how you prosecute applications and enforce issued patents. But it won't shield a commercial acquisition that was anticompetitive from the start.
The FTC's brief, authorized by a 2-0 Commission vote and filed in the U.S. Court of Appeals for the Fourth Circuit, signals that regulators are paying attention to these transactions. That doesn't mean panic. It means diligence. Treat patent application acquisitions the way you'd treat any other deal that affects market structure. Ask the competitive effects questions before you sign, not after you're defending a Section 2 claim.
